Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ADAPTIVE BIOTECHNOLOGIES CORPORATION reported revenue of $277M, up 54.8% year over year. Operating margin was -20.6% and net margin -21.5%, on a free-cash-flow margin of -17.7% with capital expenditure at 1.1% of revenue. Every figure is computed directly from ADPT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $277M | -20.6% | -21.5% |
| FY2024 | $179M | -90.8% | -89.1% |
| FY2023 | $170M | -133.3% | -132.3% |
| FY2022 | $185M | -108.0% | -108.0% |
| FY2021 | $154M | -135.4% | -134.3% |
How does ADPT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.